Interviews with Pharma and Biotech Global Leaders
Refine Search
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Pharmaceutical
When faced with criticism over drug prices, pharma companies can point to figures which reveal how little of countries’ healthcare budgets go towards prescription medicines. 13 April 2017
Biotechnology
When Swedish Orphan Biovitrum announced its financial results in February, all eyes were on the Stockholm-based firm’s hemophilia portfolio. 12 April 2017
Pharmaceutical
A stellar performance from the diabetes drug Jardiance (empagliflozin) is keeping Germany’s Boehringer Ingelheim firmly on the path to growth as it prepares for the loss of patent protection on its chronic obstructive pulmonary disease blockbuster Spiriva (tiotropium). 6 April 2017
Pharmaceutical
For almost a century, Danish diabetes care giant Novo Nordisk has been developing insulins and treatments for people with diabetes. 6 April 2017
Pharmaceutical
The chief executive for the UK and Ireland at German pharma major Bayer is spending 30% of his time working on issues related to Brexit, he said this week. 1 April 2017
Pharmaceutical
Before Theresa May signed the decree absolute, Ireland began preparing its bid to become the new home of the European Medicines Agency (EMA). 29 March 2017
Pharmaceutical
As senior vice president for the global business franchise fertility at German pharma major Merck KGaA, Dorothea Wenzel has been tasked with deciding what to do now that her company has achieved the “gold standard” drug in this space. 22 March 2017
Biotechnology
Denise Scots-Knight has developed a formula for success that’s seen her company, Mereo BioPharma, go from zero to IPO within a year. 17 March 2017
Pharmaceutical
The chance to focus on an area of massive unmet medical need was a major factor in attracting Gabriel Baertschi to leave his previous role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 7 March 2017
Pharmaceutical
“A focused strategy but one that’s diverse within the areas of focus that we have” sums up the approach of Bayer and Robert LaCaze in oncology as they set their sights on making a big difference in this highly competitive and rapidly evolving environment. 2 March 2017
Biotechnology
Ovid’s metamorphosis from fledgling biotech startup to global rare disease specialist with epic ambitions began just two years ago with $5 million in venture capital. Now guiding the process is chief executive Jeremy Levin, who spoke to The Pharma Letter from the company’s New York headquarters about Ovid’s recent partnership with Japan’s largest drugmaker Takeda Pharmaceutical, a firm with $16 billion in revenue and some 30,000 employees. 28 February 2017
Pharmaceutical
Isabel Torres, global head for access to medicine at Japanese pharma major Takeda Pharmaceutical, tells The Pharma Letter about its Access to Medicine (AtM) strategy. 17 February 2017
Pharmaceutical
Carole Longson spent eight years developing novel pharmaceuticals at GlaxoSmithKline, before crossing the floor to join the UK’s national health watchdog, the National Centre for Health and Care Excellence (NICE). The Pharma Letter speaks with her about the importance of cost-effectiveness, the value of the revised Cancer Drugs Fund, the growing role played by real-world evidence, and her hopes for a positive decision on Kadcyla (trastuzumab emtansine). 8 February 2017
Pharmaceutical
French pharma group Ipsen’s acquisition of the oncology assets of Merrimack Pharmaceuticals (Nasdaq: MACK), which was announced in the first working week of 2017, was potentially evidence not just of a busy year to come in mergers and acquisitions (M&A) for the pharma sector. 1 February 2017
Biotechnology
Dompé chief executive Eugenio Aringhieri is realizing an ambitious plan to transform the privately owned, fully integrated company into an innovative and truly global biotech leader, the first of its kind in Italy. 23 January 2017
Pharmaceutical
Given that it is best known for its aesthetic potential in reducing facial wrinkles, few people will know that Botox (onabotulinumtoxinA) has as many as 11 separate therapeutic indications, treating conditions ranging from overactive bladder to chronic migraines. 16 January 2017
Biotechnology
Lan Huang is no stranger to awards, from being named Soroptimist International’s international-level Women’s Opportunity Award in 1997 alongside her biophysical chemistry PhD from the University of California, Berkeley, to picking up China’s Thousand Talent Innovator prize in 2009. 9 January 2017
Biotechnology
Be it in constantly improving the fundamentals of its Affimer technology, engaging with pharma partners on drug discovery programs or developing its own therapeutics pipeline focusing on immuno-oncology and bleeding disorders, UK biotech Avacta is moving fast to maximize the potential of these non-antibody binding proteins. 11 December 2016
Biosimilars
Roman Ivanov, vice president of research and development (R&D) at Biocad, describes his company’s current transition as going from being a local biosimilar player in its native Russia, to a global mid-sized biopharmaceutical player, in an intreview with The Pharma Letter's Guy Martin. 29 November 2016
Pharmaceutical
Guido Rasi, executive director of the European Medicines Agency (EMA), has seen some huge steps being taken by the regulator since he first took on the role in 2011. 21 November 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze